When tumor cells with high expression of HSPA4 are treated with PD1 blockade therapy, CD8+ T cells are re-activated and cell toxicity is restored, then tumor cells respond better to PD1 checkpoint blockade therapy (Fig. 7). This evidence concerns the gene CD8A and neoplasm.